Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-263 vs Opdivo in Advanced Melanoma
NCT06640530Phase 3Active, not recruiting
- Sponsor
- BIOCAD
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of BCD-263 in melanoma, sponsored by BIOCAD. Started Mar 2024; status: active, not recruiting.
02
Drugs
BCD-263
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06640530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640530.